Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 10, 2013, Pages 855-864

  Byrne, Michael ^a   Tzekov, Radouil ^b,c   Wang, Yi ^b   Rodgers, Amanda ^a   Cardia, James ^a   Ford, Glenna ^a   Holton, Katherine ^a   Pandarinathan, Lakshmipathi ^a   Lapierre, Jennifer ^a   Stanney, William ^a   Bulock, Karen ^a   Shaw, Sharon ^a   Libertine, Lyn ^a   Fettes, Kevin ^a   Khvorova, Anastasia ^a,b   Kaushal, Shalesh ^b   Pavco, Pamela ^a  

^a RXi Pharmaceuticals Corporation   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c ROSKAMP INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SD RXRNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; GENE SILENCING; GENETIC TRANSFECTION; HYDROPHOBICITY; IN VITRO STUDY; INTERNALIZATION; MALE; NONHUMAN; RNA ANALYSIS; RNA ISOLATION; SIGNAL NOISE RATIO; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; WILD TYPE;

ANIMALS; CELL LINE; EYE DISEASES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INTRAVITREAL INJECTIONS; MICE; MICE, INBRED C57BL; RABBITS; RETINA; RETINAL PIGMENT EPITHELIUM; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS;

EID: 84890082930     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0148     Document Type: Article

References (23)

1. Castanotto, D., and Rossi, J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 457:426-433, 2009.
2. Bumcrot, D., Manoharan, M., Koteliansky, V., and Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2:711-719, 2006.
3. Rettig, G.R., and Behlke, M.A. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20:483-512, 2011.
4. de Fougerolles, A., Vornlocher, H.P., Maraganore, J., and Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug. Discov. 6:443-453, 2007.
5. Crooke, R.M., Graham, M.J., Lemonidis, K.M., Whipple, C.P., Koo, S., and Perera, R.J. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid. Res. 46:872-884, 2005.
6. Akdim, F., Stroes, E.S., Sijbrands, E.J., Tribble, D.L., Trip, M.D., Jukema, J.W., Flaim, J.D., Su, J., Yu, R., Baker, B.F., Wedel, M.K., and Kastelein, J.J. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein, B., in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55:1611-1618, 2010.
7. Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., Tribble, D.L., Flaim, J.D., and Crooke, S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 375:998-1006, 2010.
8. Chu, C.Y., and Rana, T.M. Potent RNAi by short RNA triggers. RNA. 14:1714-1719, 2008.
9. Sun, X., Rogoff, H.A., and Li, C.J. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol. 26:1379-1382, 2008.
10. Chang, C.I., Yoo, J.W., Hong, S.W., Lee, S.E., Kang, H.S., Sun, X., Rogoff, H.A., Ban, C., Kim, S., Li, C.J., and Lee, D.K. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol. Ther. 17:725-732, 2009.
11. Schlee, M., Hornung, V., and Hartmann, G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14:463-470, 2006.
12. Whitehead, K.A., Dahlman, J.E., Langer, R.S., and Anderson, D.G. Silencing or stimulation? siRNA delivery and the immune system. Annu. Rev. Chem. Biomol. Eng. 2:77-96.
13. Zamanian-Daryoush, M., Marques, J.T., Gantier, M.P., Behlke, M.A., John, M., Rayman, P., Finke, J., and Williams, B.R. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J. Interferon. Cytokine. Res. 28:221-233, 2008.
14. Daffis, S., Szretter, K.J., Schriewer, J., Li, J., Youn, S., Errett, J., Lin, T.Y., Schneller, S., Zust, R., Dong, H., Thiel, V., Sen, G.C., Fensterl, V., Klimstra, W.B., Pierson, T.C., Buller, R.M., Gale, M., Jr., Shi, P.Y., and Diamond, M.S. 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature. 468:452-456.
15. Geisert, E.E., Lu, L., Freeman-Anderson, N.E., Templeton, J.P., Nassr, M., Wang, X., Gu, W., Jiao, Y., and Williams, R.W. Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice. Mol. Vis. 15:1730-1763, 2009.
16. Recchia, F.M., Xu, L., Penn, J.S., Boone, B., and Dexheimer, P.J. Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest. Ophthalmol. Vis. Sci. 51:1098-1105, 2010.
17. Strauss, O. The retinal pigment epithelium in visual function. Physiol. Rev. 85:845-881, 2005.
18. Kleinberg, T.T., Tzekov, R.T., Stein, L., Ravi, N., and Kaushal, S. Vitreous substitutes: a comprehensive review. Surv. Ophthalmol. 56:300-323, 2011.
19. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., Racie, T.S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K.N., Maier, M., Nechev, L., Rajeev, K.G., Read, T., Rohl, I., Soutschek, J., Tan, P., Wong, J., Wang, G., Zimmermann, T., de Fougerolles, A., Vornlocher, H.P., Langer, R., Anderson, D.G., Manoharan, M., Koteliansky, V., Horton, J.D., and Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U S A. 2008.
20. Brigell, M., Dong, C.J., Rosolen, S., and Tzekov, R. An overview of drug development with special emphasis on the role of visual electrophysiological testing. Doc. Ophthalmol. 110:3-13, 2005.
21. Kleinman, M.E., Kaneko, H., Cho, W.G., Dridi, S., Fowler, B.J., Blandford, A.D., Albuquerque, R.J., Hirano, Y., Terasaki, H., Kondo, M., Fujita, T., Ambati, B.K., Tarallo, V., Gelfand, B.D., Bogdanovich, S., Baffi, J.Z., and Ambati, J. Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3. Mol. Ther. 101-108, 2012.
22. Eljarrat-Binstock, E., Pe'er, J., and Domb, A.J. New techniques for drug delivery to the posterior eye segment. Pharm. Res. 27:530-543, 2010.
23. Kleinman, M.E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J.Z., Albuquerque, R.J., Yamasaki, S., Itaya, M., Pan, Y., Appukuttan, B., Gibbs, D., Yang, Z., Kariko, K., Ambati, B.K., Wilgus, T.A., DiPietro, L.A., Sakurai, E., Zhang, K., Smith, J.R., Taylor, E.W., and Ambati, J. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 452:591-597, 2008.